Home Newsfeeds Needham Maintains Buy on PhaseBio Pharmaceuticals, Lowers Price Target to $8

Needham Maintains Buy on PhaseBio Pharmaceuticals, Lowers Price Target to $8

Needham analyst Serge Belanger maintains PhaseBio Pharmaceuticals (NASDAQ:PHAS) with a Buy and lowers the price target from $10 to $8.

byBenzinga Newsdesk

August 15, 2022

1 minute read

Needham analyst Serge Belanger maintains PhaseBio Pharmaceuticals (NASDAQ:PHAS) with a Buy and lowers the price target from $10 to $8.

News

SoftBank Group and Symbotic Establish New Warehouse-as-a-Service Joint Venture To Transform Supply Chain Services Through Automation and AI; Symbotic Expects Over $500M In Incremental Revenue

By Benzinga Newsdesk

July 24, 7:07 AM

SoftBank Group Corp. (TSE: 9984, "SoftBank") and Symbotic Inc. (NASDAQ:SYM), a leader in A.I.-powered automation technology for the supply chain, today announced the establishment of GreenBox Systems

SFTBF

This Chinese Teen Built A Bitcoin Exchange And Lost Out On $6B When It Got Hacked

By Khyathi Dalal

May 20, 10:44 AM

Bitcoin Magazine editor Pete Rizzo took to his X account to share the story of Zhao Tong, who created the first-ever crypto margin exchange, Bitcoinica, and ultimately lost 99,000 Bitcoin (CRYPTO: BTC)

BTC